key: cord-0890125-09l2enef authors: Weber, Christopher J.; Carrillo, Maria C.; Jagust, William; Jack, Clifford R.; Shaw, Leslie M.; Trojanowski, John Q.; Saykin, Andrew J.; Beckett, Laurel A.; Sur, Cyrille; Rao, Naren P.; Mendez, Patricio Chrem; Black, Sandra E.; Li, Kuncheng; Iwatsubo, Takeshi; Chang, Chiung‐Chih; Sosa, Ana Luisa; Rowe, Christopher C.; Perrin, Richard J.; Morris, John C.; Healan, Amanda M.B.; Hall, Stephen E.; Weiner, Michael W. title: The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives date: 2021-12-31 journal: Alzheimers Dement (N Y) DOI: 10.1002/trc2.12226 sha: 6ad0cef4d1ce9988e8fddd5c1c84b3a1860317b0 doc_id: 890125 cord_uid: 09l2enef The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW‐ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public‐private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI‐1, ADNI‐GO, ADNI‐2, and ADNI‐3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW‐ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW‐ADNI researchers who shared updates from ADNI‐3 and their vision for ADNI‐4. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, naturalistic study to understand structural, biochemical, and cognitive changes that occur during Alzheimer's disease (AD) progression. ADNI investigators leverage imaging, blood, and cerebrospinal fluid (CSF) analysis, and clinical, genetic, and postmortem neuropathologic databases to define markers for each stage of AD. 1 Data obtained through ADNI are used to inform clinical trial design and sufficiently power trials. ADNI data can also help establish outcome measures and identify appropriate trial participants. North American ADNI investigators are organized into distinct cores centered around: positron emission tomography (PET), magnetic resonance imaging (MRI), fluid (blood, CSF) biomarkers, genetics, biostatistics, autopsy neuropathology, and clinical data with an informatics core for widespread data sharing without embargo. More broadly, Worldwide ADNI (WW-ADNI) now encompasses neuroimaging initiatives from nine distinct regions. It serves as the umbrella organization for North American ADNI, Argentina ADNI, Australia ADNI (AIBL), Canada ADNI, China ADNI, Japan ADNI, Korea ADNI, Mexico ADNI, and Taiwan ADNI. Biologic samples are shared and all WW-ADNI investigators are tasked with harmonizing research methodologies so that data can be readily combined. WW-ADNI is the result of several successive phases. The first phase, ADNI-1, launched in 2004. ADNI-1 established much of the organizational structure still in place within the North American ADNI, including core facilities. 2, 3, 4 In total, 821 participants with and without mild cognitive impairment (MCI) or AD enrolled in ADNI-1 across 57 study sites. 1 Two subsequent phases followed: ADNI "Grand Opportunities" (ADNI-GO) and ADNI-2. ADNI-GO supported amyloid PET scans for ADNI-1 participants plus enrollment of 200 early MCI participants. 5 ADNI-2 further expanded the study population by 550 to include people with other forms of memory impairment. The PET core has amassed thousands of brain PET scans that can be downloaded by qualified users. The scans employ 18 The MRI core uses several sequences, including three-dimensional (3D) T1 volume, 3D fluid-attenuated inversion recovery (FLAIR), and T2* gradient echo (GRE), plus associated measurements. The core's technical capacities also include diffusion-weighted MRI (dMRI), arterial spin labeling (ASL) in 2D and 3D, task-free functional MRI (TF-fMRI), and coronal high-resolution T2 sequences. 5, 12 The core has developed standardized protocols 5 for these sequences that can be employed across WW-ADNI. The core has developed basic and advanced protocols 9 to accommodate MRI system variability and evolving operating systems. ADNI-3 imaging is being performed exclusively on 3T scanners. The core is performing meta-analyses of site-specific effects, 13 random-effects regressions to identify scanner-specific effects, and adjusting data before pooling 14 or encoding it to eliminate bias. 15 A newly identified risk has been the potential identification of participants based on MRI, through publicly available facial recognition software. 16 With ADNI-3, the Biomarker core's collection of CSF, plasma, and serum grew by > 1700 samples for new enrollees and > 1600 for rollover participants. More than half (55%) of all new participants have received a lumbar puncture. The core has standardized biofluid collection and processing 18, 19 across WW-ADNI sites. The core has also standardized ultraperformance liquid chromatography-tandem mass spectrometry (MS) 3,20 and multiplexed MS. 21 In ADNI-3, the core revised their protocol to reduce total collection time for plasma samples to under 1 hour. The core has worked with the Foundation for the National Institutes of Health -Biomarkers Consortium (FNIH -BC) to conduct a multicenter study using replicate sets of 130 ADNI plasma aliquot samples distributed to each of six participating centers. Results and analyses will be conducted in early 2021. The core has shipped >30,000 aliquots to researchers around the world who provided data for additional pathologic pathways (eg, neurogranin, Neurofilament light chain (NfL), soluable triggering receptor expressed on myeloid cells 2 (sTREM2), Neuronal Pentraxin 2 (NPTX2)) following review and approval by the WW-ADNI Resource Allocation Review Committee (RARC). [21] [22] [23] [24] RARC is made up of non-ADNI investigators and serves as a gatekeeper for this precious resource. In anticipation of increased plasma sample requests in ADNI-4, the core is investigating how factors such as delayed centrifugation, aliquot size, and multiple freeze-thaw cycles affect AD biomarker integrity. Concentration values for the core CSF biomarkers have been determined on >3000 CSF samples collected in the ADNI-1/-GO/-2 and -3 Phases using the highly standardized automated Roche Elecsys system. Although many studies that use Genetics core data focus on APOE and other risk variants, 25 ADNI-3 has brought collaborations to study polygenic risk scores, epigenetics, transcriptomics, proteomics, and metabolomics. For example, one group integrated data from six multicenter cohort studies (4314 participants). The group successfully identified common variants in RBFOX1 associated with early brain amyloidosis. 26 Another identified genetic determinants of hippocampal volume in 33,536 individuals. 27 For Ribonucleic acid (RNA), genomewide transcriptome analyses of ADNI core data identified novel genes dysregulated in AD pathology: CREB5, CD46, TMBIM6, IRAK3, and RPAIN. 28 An epigenome-wide association study identified differentially methylated profiles in peripheral blood between MCI and AD participants. 29 Metabolomics researchers within the Genetics core found sex-specific effects. APOE ε4-positive women experience greater mitochondria impairment than men do. 30 In ADNI-4, the group plans to extend polygenic analyses. The core is also testing deep learning as an approach to analyzing multilayer -omics data. This year, due to disruptions caused by the coronavirus disease 2019 (COVID-19) pandemic, the Biostatistics core has been investigating the impact of missing data on longitudinal modeling and analyses. This includes determining whether data collected at home are comparable to clinic data. Participants in CogState studies, 14 for example, complete cognitive tests both at home and in a clinic, with significantly faster response times at home. The core is developing approaches to accommodate this factor when analyzing future cognitive testing data, including in ADNI-4. The core is also investigating the effects of attrition or scheduling abnormalities caused by COVID-19. The core is determining how adjusting data collection timing (an early or late timestamp) impacts planned analyses and power. Biostatistics core simulations show that a generalized additive mixed-models approach has more power that a mixed model for repeated measures to detect differences when there is a study hiatus, especially if the gap in data collection is long. 31 In anticipation of ADNI-4, the core is also developing models that allow for time as a continuous (rather than categorical, or timestamped) measurement. This will support adaptations that preserve power even if there are measurement gaps due to COVID-19 or unforeseen circumstances. In its original funding period, ADNI-1 did not have provisions for the neuropathologic assessment of deceased ADNI participants or for the establishment of a brain tissue resource; hence, ADNI began without a Neuropathology Core (NPC). The ADNI NPC was established in 2007 as a "sub-study" of ADNI- In addition, 85% of the participants whose dementia likely was caused by AD pathology also exhibited features of at least one other neurodegenerative disease with the potential to have contributed to their illness. These findings underscore how essential that neuropathologic confirmation will be for ADNI to develop truly accurate biomarkers for AD and related dementias. Recognizing the vital importance of neuropathologic confirmation and the potential value of a large brain tissue resource for the discovery and validation of molecular biomarkers of AD and other neurodegenerative pathologies, ADNI Leadership helped the NPC to secure two administrative supplements from the NIA in 2019 and 2020. The first strengthened the central infrastructure and staffing of the ADNI NPC; the second is working to bolster the brain donation program across the entire North American ADNI network. Over the past 2 years, these investments have allowed the ADNI NPC to expand its resource to >115 brain donations, to identify at least 50 additional ADNI-participant brain donations previously assessed at participating ADRCs, to increase support of ADNI brain donation efforts at participating sites, and to persuade several ADNI sites to join ADNI's brain donation program network for the first time. As ADNI-4 approaches, the ADNI-NPC will continue its efforts to strengthen and build new connections within the ADNI brain donation network, to expand the tissue resource, and to comprehensively assess all donated specimens for relevant neuropathology. In ADNI-4, the NPC will additionally actively promote, coordinate, and participate in the study of this resource, governed by the ADNI Neuropathol- Funding for US ADNI-3 ends August 2022, and ADNI-4 planning is underway (Figure 1) . A renewal grant for ADNI-4 was submitted to the NIA in Oct 2021. ADNI posted a Request for Proposals on the ADNI website, and received more than 30 responses for plasma, PET, and digital biomarkers. ADNI-4 will be similar to ADNI-3, with several major additions: First, to make ADNI more generalizable, the exclusion criteria will be relaxed. In addition, an Engagement Core will focus on recruiting many more people from the Black, Latino, and Asian commu-nities, and people with lower socioeconomic status. Second, because of the excitement concerning use of plasma AD markers, ADNI-4 plans to obtain blood from 4000 participants and use the results to select 500 for referral to the ADNI clinics for in-person evaluation, MRI, PET scans, blood tests, genetics, and lumbar puncture. Finally, ADNI is exploring greater use of digital biomarkers. WW-ADNI provides a larger platform for ADNI researchers to collaborate. This aligns with a major goal of ADNI throughout its evolution: to standardize protocols and analyses, and to facilitate open access to comparable, worldwide data. 3 A Buenos Aires team has carried out the ADNI-2 protocol 3 in 56 participants under its own financial support. The team has ended ADNI follow-up visits and is now focused on data analysis. Several findings have been described. 3, 32 Participant retention was strong for the 12- Argentina ADNI researchers investigated biomarker profiles for all participants. 33, 34 At baseline, 85% of the participants in the AD group were positive on amyloid PET scans, for CSF p-tau, and for neurodegeneration. Whereas in the MCI group, this dropped to 50% for suspected non-Alzheimer's pathophysiology participants who were only positive for neurodegeneration at baseline. After 5 years of follow-up, the overall conversion rate to dementia was 21%. Cognitive testing data significantly correlated with CSF amyloid levels in participants 35 ; however, total CSF tau and p-tau were the strongest conversion predictors. 34, 36 The researchers have described the capacity of several biomarkers to predict cognitive impairment. 37, 38 Notably, Argentina ADNI is the first group in Latin America to perform tau PET scans (23 performed to date). Canada ADNI is conducting a multisite amyloid and (18) At baseline and 24 months, study participants completed 3T MRI, 18 F-florbetapir, and 18 F-FDG-PET scans, blood draws, and gait and cognitive testing. Preliminary analyses compare 57 participants with moderate to severe pvWMH to 57 ADNI-2 MCI or AD participants with minimal pvWMH. Overall, higher pvWMH was associated with elevated brain amyloid burden by PET scan. Participants with minimal pvWMH had lower brain glucose levels. 39 Random forest machinelearning algorithms pinpointed several brain regions associated with cognitive ability, most strikingly, the posterior cingulate gyrus. Lower amyloid burden and increased glucose in this region was associated with higher cognitive test scores. 40 Methods developed by Canada ADNI suggest that simple machine learning can help classify regions of interest in PET scans. Taiwan ADNI infrastructure has enabled researchers to assess changes in amyloid deposition due to carotid artery stenosis 50 and traumatic brain injury. 51 It has also supported PET imaging to better understand how D678H, a familial autosomal mutation common in Taiwan, may increase AD risk. 52 56 Through international collaboration, AIBL is investigating binding of an F-18-labeled tracer to MAO-B, to assess reactive astrocytosis during the development of AD. 57 Australia ADNI has collaborated with industry partners to ramp up production of tau MK6240 and amy-loid NAV4694 tracers at five production sites to accommodate growing research needs. WW-ADNI has made major strides in amyloid and tau phenotyping, standardizing methodologies, and providing a rich data set for AD researchers around the globe. The group's efforts serve as a foundation for AD treatment trials. WW-ADNI findings can inform participant selection criteria and deeply enhance outcome measures. As WW-ADNI continues, a major goal will be to validate biomarkers identified to date, with focus on their generalizability and relationships to cognitive decline and dementia symptoms. A goal shared by all WW-ADNI researchers is to enroll more racial and ethnic minorities. To accomplish this, ADNI-4 may relax exclusion criteria related to comorbidities across cognitively unimpaired, MCI, and AD cohorts. This may include allowing participants previously exposed to disease-modifying treatments. Specific inclusion criteria changes will be made in collaboration with the PPSB. ADNI-4 will also allow release of amyloid PET results to participants. This modification is based upon feedback from current study participants and is expected to further support recruitment efforts. ADNI-4 will include a plasma-based screening effort that selects eligible participants for imaging and CSF collection. ADNI-4 is also expected to scale up autopsy neuropathology data collection. If funded, ADNI-4 is expected to begin in August 2022. Elecsys is a registered trademark of Roche. CCC's WW-ADNI project is sponsored by Chang Gung Memo- WJ has served as a consultant to Bioclinica, Biogen, CuraSen, Grifols, and Roche/Genentech. CRJ serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception The Alzheimer's disease neuroimaging initiative Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative The Alzheimer's disease neuroimaging initiative: progress report and future plans Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative Perspective: the Alzheimer's disease neuroimaging initiative and the role and contributions of the private partner scientific board Understanding disease progression and improving Alzheimer's disease clinical trials: recent highlights from the Alzheimer's disease neuroimaging initiative The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals NIA-AA Research Framework: toward a biological definition of Alzheimer's disease Alzheimer's disease neuroimaging initiative. longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer's disease pathophysiology Magnetic resonance imaging in Alzheimer's neuroimaging initiative 2 Identification of common variants associated with human hippocampal and intracranial volumes Adjusting batch effects in microarray expression data using empirical Bayes methods Scanner invariant representations for diffusion MRI harmonization Identification of anonymous MRI research participants with face-recognition software Data use under the NIH GWAS data sharing policy and future directions The Alzheimer's disease neuroimaging initiative 2 biomarker core: a review of progress and plans Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research Analytical and clinical performance of amyloid-beta peptides measurements in CSF of ADNIGO/2 participants by an LC-MS/MS reference method Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's disease neuroimaging initiative (ADNI) CSF Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimers Dement Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease Associations of the top 20 Alzheimer disease risk variants with brain amyloidosis Association between common variants in RBFOX1, an RNA-binding protein, and brain amyloidosis in early and preclinical Alzheimer disease Novel genetic loci associated with hippocampal volume Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology Harnessing peripheral DNA methylation differences in the Alzheimer's disease neuroimaging initiative (ADNI) to reveal novel biomarkers of disease Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome Alternatives to MMRM for preclinical Alzheimer's clinical trials 2020.JSM 2020 Virtual Conference Prognostic value of ATN Alzheimer's biomarkers: 60-month follow-up results from the Argentine Alzheimer's disease neuroimaging initiative Alzheimer's disease neuroimaging initiative (Arg-ADNI): neuropsychological evolution profile after one-year follow up Neuropsychological profile of Alzheimer's disease based on amyloid biomarker findings results from a South American cohort Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer's disease neuroimaging initiative) A biological classification for Alzheimer's disease -Amyloid, tau and neurodegeneration (A/T/N): results from the Argentine-Alzheimer's disease neuroimaging initiative Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic Predicting episodic memory performance using different biomarkers: results from Argentina-Alzheimer's disease neuroimaging initiative. Neuropsychiatr Dis Treat The use of random forests to identify brain regions on amyloid and FDG PET associated with MOCA score The use of random forests to classify amyloid brain PET An fMRI study of neuronal specificity in acupuncture: the multiacupoint siguan and its sham point. Evid Based Effect of acupuncture in mild cognitive impairment and Alzheimer's disease: a functional MRI study Acupuncture stimulation of Taichong (Liv3) and Hegu (LI4) modulates the default mode network activity in Alzheimer's disease Acupuncture modulates resting state hippocampal functional connectivity in Alzheimer's disease Modulation of functional activity and connectivity by acupuncture in patients with Alzheimer's disease as measured by resting-state fMRI The long-term effects of acupuncture on hippocampal functional connectivity in amci with hippocampal atrophy: a randomized longitudinal fMRI study Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: harmonization for international trials Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease Predicting amyloid risk by machine learning algorithms based on the A4 screen data: application to the Japanese Trial-Ready Cohort study Amyloid deposition after cerebral hypoperfusion: evidenced on [(18)F]AV-45 positron emission tomography Accumulation of amyloid in cognitive impairment after mild traumatic brain injury Amyloid PET pattern with dementia and amyloid angiopathy in Taiwan familial AD with D678H APP mutation Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: evidence of cerebral amyloidosis and hippocampal atrophy Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET Association of β-Amyloid level, clinical progression and longitudinal cognitive change in normal older individuals The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives